Miguel Fidalgo

Miguel Fidalgo obtained his PhD in 2010 in Molecular Medicine at the University of Santiago de Compostela (Spain). The goal of his PhD training was to find out novel signaling pathways affected by oxidative stress in two relevant pathophysiological conditions (cancer and vascular malformations). Then in 2011, he moved to Icahn School of Medicine at Mount Sinai (ISMMS, NY, USA) and shifted his research interests into the Stem Cell field by studying the transcriptional and epigenetic regulation of stem cell pluripotency and somatic cell reprogramming. In April 2016, He returned to Spain with a Ramón y Cajal Award to set up his laboratory. Currently, his group is interested in understanding epigenetic and epitranscriptomic regulation of transcription in the mammalian genome that governs cell fate decisions during embryonic development and human diseases. His group aims to develop novel therapeutic strategies for metabolic- and age-related disorders as well as rare diseases. For this purpose, his group uses a variety of methods in molecular biology, genomic and proteomic approaches, genome editing and bioinformatics.